Trials / Completed
CompletedNCT00150384
Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 500 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amlodipine/Atorvastatin |
Timeline
- Start date
- 2004-07-01
- Completion
- 2005-08-01
- First posted
- 2005-09-08
- Last updated
- 2021-01-27
Locations
106 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00150384. Inclusion in this directory is not an endorsement.